Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: A review

International Journal of Neuroscience

Volumn 121, Issue 9, 2011, Pages 485-489

  Silver, Dee E ^a   Buck, Philip O ^b  

^a Coast Urology Medical Group Inc   (United States)

^b Teva Neuroscience Inc   (United States)

Author keywords

Bradykinesia; Motor symptoms; Parkinson's disease; Rasagiline; UPDRS

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE;

BRADYKINESIA; DISEASE SEVERITY; DRUG EFFICACY; EMBASE; HUMAN; MEDLINE; MONOTHERAPY; PARKINSON DISEASE; PARKINSON DISEASE QUALITY OF LIFE QUESTIONNAIRE; QUESTIONNAIRE; REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE;

DATABASES, FACTUAL; HUMANS; HYPOKINESIA; INDANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 80051521526     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.582240     Document Type: Review

References (28)

1. Cummings, J. L., & Masterman, D. L. (1999). Depression in patients with Parkinson's disease. International Journal of Geriatric Psychiatry, 14(9), 711-718. (Pubitemid 29450282)
2. de Boer, A. G., Wijker, W., Speelman, J. D., & de Haes, J. C. (1996). Quality of life in patients with Parkinson's disease: Development of a questionnaire. Journal of Neurology, Neurosurgery, and Psychiatry, 61(1), 70-74. (Pubitemid 26232031)
3. de Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson's disease. Lancet Neurology, 5(6), 525-535. (Pubitemid 44262284)
4. Fahn, S., & Elton, R. (1987). Unifed Parkinson's disease rating scale. In S. Fahn, C. D. Marsden, D. B. Calne, & M. Goldstein (eds.), Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information, 153-163.
5. Gasparoli, E., Delibori, D., Polesello, G., Ermani, M., Battistin, L., & Bracco, F. (2002). Clinical predictors in Parkinson's disease. Journal of Neurological Sciences, 23, S77-S78. (Pubitemid 35355785)
6. Hauser, R. A., & Auinger, P. (2011). Determination of minimal clinically important change in early and advanced Parkinson's disease. Movement Disorders, 26(5), 813-818.
7. Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427-442.
8. Koertsa, J., Leenders, K. L., Koning, M., Bouma, A., & van Beilen, M. (2008). The assessment of depression in Parkinson's disease. European Journal of Neurology, 15(5), 487-492. (Pubitemid 351499191)
9. Lang, A. E., & Lozano, A. M. (1998). Parkinson's disease. First of two parts. New England Journal of Medicine, 339(15), 1044-1053. (Pubitemid 28457867)
10. Lyons, K. E., Pahwa, R., Troster, A. I., & Koller W. C. (1997). A comparison of Parkinson's disease symptoms and self-reported functioning and well being. Parkinsonism Related Disorders, 3(4), 207-209. (Pubitemid 28188831)
11. Marras, C., Rochon, P., & Lang, A. E. (2002). Predicting motor decline and disability in Parkinson disease: A systematic review. Archives of Neurology, 59(11), 1724-1728. (Pubitemid 35340482)
12. Muslimovic, D., Post, B., Speelman, J. D., Schmand, B., & de Haan, R. J. (2008). Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology, 70(23), 2241-2247.
13. Nussbaum, R. L., & Ellis, C. E. (2003). Alzheimer's disease and Parkinson's disease. New England Journal of Medicine, 348(14), 1356-1364. (Pubitemid 36384104)
14. Olanow, C. W., Stern, M. B., & Sethi, K. (2009). The scientifc and clinical basis for the treatment of Parkinson disease. Neurology, 72(21 Suppl. 4), S1-S136.
15. Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, S., Bronte-Stewart, H., Hallet, M., Miyasaki, J., Stevens, J., & Weiner W. J. (2006). Practice parameter: Treatment of Parkinson disease with motor fuctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66, 983-995. (Pubitemid 44044780)
16. Papapetropoulos, S., Ellul, J., Argyriou, A. A., Chroni, E., & Lekka, N. P. (2006). The effect of depression on motor function and disease severity of Parkinson's disease. Clinical Neurology and Neu-rosurgery, 108(5), 465-469. (Pubitemid 43729487)
17. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Archives of Neurology, 59(12), 1937-1943.
18. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fuctuations: The PRESTO study. Archives of Neurology, 62(2), 241-248.
19. Politis, M., Wu, K., Molloy, S., Bain, G. P., Chaudhuri, K. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders, 25(11), 1646-1651.
20. Post, B., Merkus, M. P., de Haan, R. J., & Speelman J. D. (2007). Prognostic factors for the progression of Parkinson's disease: A systematic review. Movement Disorders, 22(13), 1839-1851. (Pubitemid 350134194)
21. Rascol, O. (2006). Defning a minimal clinically relevant difference for the unifed Parkinson's rating scale: An important but still unmet need. Movement Disorders, 21(8), 1059-1061. (Pubitemid 44336586)
22. Rascol, O., Brooks, D. J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fuctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet, 365(9463), 947-954. (Pubitemid 41071428)
23. Reichmann, H., & Jost, W. (2010). Effcacy and tolerability of rasag-iline in daily clinical use-A post-marketing observational study in patients with Parkinson's disease. European Journal of Neurology, 17, 1164-1171.
24. Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006). Minimal clinically important change on the unifed Parkinson's disease rating scale. Movement Disorders, 21(8), 1200-1207. (Pubitemid 44336608)
25. Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P., Reich, S. G., & Weiner, W. J. (2009). Longitudinal assessment of a clinically meaningful difference in the UPDRS. Las Vegas, NV: American Academy of Neurology.
26. Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P., Reich, S. G., & Weiner, W. J. (2010). The clinically important difference on the unifed Parkinson's disease rating scale. Archives of Neurology, 67(1), 64-70.
27. Teva Pharmaceutical Industries Ltd. (2006). Azilect (rasagiline mesy-late) prescribing information. Kfar Saba, Israel: Author.
28. Wilson, R. E., Buck, P. O., Conner, J. B., & Castelli-Haley, J. (2011). Psychometric examination of the UPDRS bradykinesia subscale. Toronto, ON: Movement Disorders Society.